Background. - Completeness, timeliness and accuracy are important qualities for registries. The objective was to estimate the completeness of the first two years of full registration (2008/2009) of a new population-based general cancer registry, at the time of national data centralisation. Methods. - Records followed international standards. Numbers of cases missed were estimated from a three-source (pathology labs, healthcare centres, health insurance services) capture-recapture method, using log-linear models for each gender. Age and place of residence were considered as potential variables of heterogeneous catchability. Results. - When datawere centralized (2011/2012), 4446 cases inmen and 3642 inwomenwere recorded for 2008/2009 in the Registry. Overall completenesswas estimated at 95.7% (95% CI: 94.3-97.2) for cases in men and 94.8% (95% CI: 92.6-97.0) in women. Completeness appeared higher for younger than for older subjects, with a significant difference of 4.1% (95% CI: 1.4-6.7) formen younger than 65 compared with their older counterparts. Estimateswere collatedwith the number of cases registered in 2014 for the years 2008/2009 (4566 cases for men/3755 for women), when additional structures had notified cases retrospectively to the Registry. These numbers were consistent with the stratified capture-recapture estimates. Conclusion. -This method appeared useful to estimate the completeness quantitatively. Despite a rather good completeness for the new Registry, the search for cases among older subjects must be improved. (C) 2019 Elsevier Masson SAS. All rights reserved.

Background. - Non-Hodgkin's lymphomas (NHL) are the seventh most commonly diagnosed cancer in France. Nord-Pas-de-Calais is ranked as the region with the highest incidence of cancers and deaths by cancer in France. With its rich industrial past and its contrasted population densities between urban and rural territories, Nord-Pas-de-Calais represents a geographic area of interest to study the overall incidence of NHL and examine spatial variation of NHL incidence between the 170 cantons of the region. Methods. - LYMPHONOR was a population-based multicentre retrospective study of patients residing in the Nord-Pas-de-Calais region and diagnosed with NHL between January 2001 and December 2005. Spatial distribution of NHL incidence in Nord-Pas-de-Calais was explored using two complementary approaches: adjusted smoothed standardised incidence ratio (SIR) and spatial scan statistics (detection of atypical clusters). Results. - Between 2001 and 2005, 2132 new cases of NHL were diagnosed in the Nord-Pas-de-Calais region. In 2005, age-standardised NHL incidence rates were 10.2 and 7.0 cases per 100,000 person-years in male and female residents, respectively. No significant spatial disparities in NHL incidence were found within the Nord-Pas-de-Calais region. The age-adjusted smoothed SIR varied from 0.82 to 1.25 between cantons. Consistently, spatial scan statistics did not detect any significant atypical cluster of high NHL incidence. Conclusion. - Comparison with national data collected during the same period does not show an overincidence of NHL in the Nord-Pas-de-Calais region. In addition, no evidence for spatial heterogeneity and clustering of NHL incidence was found within this region. Future epidemiological research using large-scale registries is needed to better appraise spatial variation of NHL incidence in France and to investigate possible reasons for significant clusters. (C) 2019 Published by Elsevier Masson SAS.

Tuteur : Dr J. Jégu, Laboratoire d’épidémiologie et de santé publique, Strasbourg, France. Responsable : Pr M. Velten, Laboratoire d’épidémiologie et de santé publique, centre Paul-Strauss, Strasbourg, France. Le tabac augmente le risque de premier mais aussi de second cancer primitif (SCP). Cette étude a cherché à déterminer si le risque de SCP chez les patients atteints d’un cancer lié au tabac a changé ces dernières années. Les données de douze registres de cancer français ont été utilisées pour constituer une cohorte de tous les patients ayant présenté un cancer du larynx, du poumon, de la vessie, de l’oropharynx ou de la cavité orale entre 1989 et 2010 suivis jusqu’au 30 juin 2013. L’approche par personnes–années a été utilisée pour estimer des ratios standardisés d’incidence (SIR) et des excès absolus de risque (EAR) de second cancer métachrone. Les tendances de SIR par année de diagnostic et site de premier cancer ont ensuite été modélisées par des régressions multivariées de poisson en ajustant sur le sexe, l’âge et la durée de suivi. Parmi les 83 166 patients ayant un premier cancer du larynx, du poumon, de la vessie, de l’oropharynx ou de la cavité orale, 7826 ont développé un SCP (SIR = 1,99 [1,94–2,03]). Après analyse multivariée par régression de poisson, seul le risque de cancer du poumon après un cancer de la vessie était associé à l’année de diagnostic du premier cancer, avec un SIR augmentant de 2,51 (95 % CI 2,06–3,02) en 1989–1994 à 3,69 (95 % CI 3,11–4,34) en 2005–2010. Le risque était stable sur la période d’étude pour les autres cancers liés au tabac. Le risque de second cancer du poumon après un cancer de la vessie ayant augmenté entre 1989 et 2010 et les risques de second cancer après un premier cancer du larynx, du poumon, de l’oropharynx et de la cavité orale étant restés hauts et inchangés, les interventions pour le sevrage tabagique des patients atteints d’un premier cancer lié au tabac doivent être poursuivies et renforcées.

Les objectifs sont de décrire les caractéristiques anatomocytopathologiques des tumeurs de vessie incidentes en population générale, dans la zone de proximité de Lille et la prise en charge thérapeutique initiale des personnes atteintes de tumeur de vessie non infiltrant le muscle (TVNIM) à risque fort de progression/récurrence et des personnes ayant une tumeur de vessie infiltrant le muscle (TVIM) au moment du diagnostic. La ZL (780 000 habitants) est couverte par le registre général des cancers de Lille et de sa région. Les tumeurs y sont enregistrées et codées selon les standards internationaux et nationaux. Les tumeurs de vessie incidentes en 2011 et 2012 sont analysées à l’exception des tumeurs bénignes et des carcinomes de l’ouraque (N = 517). Une analyse anatomopathologique a été effectuée pour 510 tumeurs. Vingt-trois pour cent des tumeurs étaient des TVNIM à faible risque de récurrence/progression, 30,8 % des TVNIM à risque intermédiaire, 17,4 % des TVNIM à haut risque et 27,5 % des TVIM. Pour les 90 tumeurs à haut risque, l’âge médian de survenue était 74 ans ; 61 cas ont été présentés en réunion de concertation multidisciplinaire (RCP) ; 49 personnes ont bénéficié d’instillations endovésicales, 9 d’une chirurgie d’emblée ; pour 90,2 %, la prise en charge initiale correspondait à la recommandation de la réunion. Pour les 142 TVIM, l’âge médian de survenue était 72 ans ; 131 cas ont été présentés en RPC ; 65 personnes ont bénéficié d’une cystectomie initiale, 32 n’ont reçu aucun traitement spécifique ; 81,5 % des personnes ont reçu le traitement préconisé. Cette description est l’une des rares études réalisées en France permettant de faire un état des lieux des tumeurs de vessie en population générale et de leur prise en charge, étape achevée par l’analyse du bilan réalisé et du timing de la prise en charge.

In this work, octadecyltrimethylammonium (ODTMA) chloride was used to prepare MCM-41 at room temperature while cetyltrimethylammonium (CTMA) bromide was used to synthesize MCM-48 and layered organosilica material under hydrothermal conditions. These synthetic organosilica materials, in addition to a commercially available organoclay, Cloisite®10A, were characterized by powder X-ray diffraction (XRD) and tested with the occluded surfactant as sorbents for nitrate. The Langmuir and Freundlich models were applied with determination of the equilibrium isotherms and the isotherm constants. Adsorption kinetics data were tested using pseudo-first-order, pseudo-second-order and intraparticle diffusion models. The results showed that the highest nitrate uptake capacities were achieved with Cloisite®10A (0.359 ± 0.003 meq/g) followed by a layered organosilica (0.287 ± 0.008 meq/g). MCM-48and MCM-41 silica adsorbed 0.096 ± 0.002 and 0.157 ± 0.005 meq/g of nitrate, respectively. Kinetics studies showed that the adsorption followed pseudo-second-order kinetic model. Layered organosilica gave a good fit to the Langmuir model among all the studied samples with correlation coefficient (R2) close to unity (0.99).

As recommended by ESMO, a final pathological diagnosis (PD) has to be obtained before any chemotherapy, radiotherapy or other non-surgical oncological therapy for pancreatic or biliary tract cancer. PD is also required for inclusion in a clinical trial. In practice, it is sometimes difficult to obtain this pathological proof because of difficult access or poor performance status. Treatment decision is then collegial, based on a clinical, radiological and biological suspicion. We studied patient survival based on availability of PD from the cancer registry of Lille and its region (800 000 inh. - North France). We reviewed patients records over 15 years old diagnosed in 2005 or 2008 for a pancreatic or biliary tract cancer (neuroendocrine excluded). The point was made on 01/12/2011. Patients were divided into 5 groups: PD and surgery (PD-Surg), PD and radiotherapy or chemotherapy (PD-RC), PD and untreat (PD-Un), no PD and radiotherapy or chemotherapy (noPD-RC), no PD and untreat (noPD-Un). Observed survival analysis was obtained from Kaplan-Meier method and statistical significance from log-rank test. Males accounted for 45.8% of 260 patients. The average age was 71.8 years (+/- 12.1). 59.6% were diagnosed as pancreas cancer. PD was not obtained in 54.2% (60% in pancreas and 45.7% in biliary tract respectively). Seven patients were lost of follow-up.unlabelled tablePD-SurgPD-RCnoPD-RCPD-UnnoPD-Unn (%)45 (17.3)44 (16.9%)37 (14.2%)30 (11.5%)104 (40%)Median survival (days)7091982037660p > 0.2p > 0.92 years survival46.7%6.8%2.9%0%2.1%

Background. - In 2005, following the first cancer plan of the national health authorities, a general cancer registry was established in northern France, in a territory designated as a "zone in proximity to the city of Lille'' (ZPL). The aim of the present work was to evaluate the completeness of the registry's first year of incident cancer registration (2005) and to compare the observed cancer incidence in the "ZPL'' with the estimated incidence in France.Methods. - Completeness was assessed using the average number of sources per case, the percentage of histological verification and a method of independent case ascertainment (mortality/incidence ratio). A direct standardization on the world population was used to calculate the ZPL/France ratios of standardized incidence rates. Analyses were conducted for 21 cancer sites.Results. - In 2005, 3635 cases of invasive cancer were recorded by the registry. The average number of sources per case was 2.7 and histological proof was available for 91.4% of cases. Mortality/incidence ratios showed satisfactory completeness of the data for men for most cancer sites. For women however, for cancer sites for which the number of cases was low, data will have to be confirmed during the subsequent years of observation. A lack of completeness was found for cutaneous melanoma. In men, an overincidence was identified for cancers of lip-mouth-pharynx, larynx, esophagus, lung, liver, bladder, kidney and colon-rectum. In women, an overincidence has been identified for cancers of lip-mouth-pharynx, liver, bladder, colon-rectum, corpus uteri and ovaries.Conclusion. - The first year of incidence validated at the "Registre general des cancers de Lille et de sa region'' shows a completeness of records with regards to studied criteria. The comparison with national data shows an overincidence of cancers related to tobacco and alcohol consumption in the geographical area covered by the registry. The incidence of lip-mouth-pharynx cancer in men is the highest of all French registries. (C) 2012 Elsevier Masson SAS. All rights reserved.

ABSTRACT Background TH-302 is a hypoxia targeted prodrug with a hypoxia-triggered 2-nitroimidazole component designed to release the DNA alkylator, bromo-isophosphoramide mustard (Br-IPM), when reduced in severe hypoxia. A randomized Phase 2B study (NCT01144455) was conducted to assess the benefit of G + T to standard dose G as first-line therapy of PAC. Materials and methods An open-label multi-center study of two dose levels of TH-302 (240 mg/m2 or 340 mg/m2) in combination with G versus G alone (randomized 1:1:1). G (1000 mg/m2) and T were administered IV over 30-60 minutes on Days 1, 8 and 15 of a 28-day cycle. Patients on the G could crossover after progression and be randomized to a G + T arm. The primary efficacy endpoint was a comparison of progression-free survival (PFS) between the combination arms and G alone (80% power to detect 50% improvement in PFS with one-sided alpha of 10%). Summary PFS outcome has previously been reported; more detailed PFS as well as the initial overall survival (OS) data are presented. Results 214 pts were treated; 164 (77%) Stage IV and 50 (23%) Stage IIIB. Median age 65 (range 29-86); 126 M/88 F; 40% ECOG 0/60% ECOG 1. Receiving 6 or more cycles: 32% G; 45% G + T240; 55% G + T340. Median PFS was 3.6 mo in G vs 5.5 mo in G + T240 (p = 0.031) and 6.0 mo in G + T340 (p = 0.008). Poorer prognostic factors (older age, poorer performance status, reduced albumin) were associated with larger treatment effect. Median OS was 7.0 mo in G vs 9.0 in G + T240 and 9.5 mo in G + T340. RECIST best response was 12% in G vs 17% in G + T240 and 27% in G + T340. CA19-9 decreases were significantly greater G + T340. A >50% CA19-9 decrease was 52% with G vs 50% with G + T240 and 70% with G + T340. AEs leading to discontinuation were: 16% G, 15% G + T240 and 11% G + T340. Rash (45% in G + T340) and stomatitis (36% in G + T340) were greater in combination, 4 pts Grade 3 rash. Grd 3/4 thrombocytopenia were 11% G, 39% G + T240 and 59% G + T340 and Grd 3/4 neutropenia were 28% G, 56% G + T240 and 59% G + T340. Conclusions The combination of G plus TH-302 improved the efficacy of G. A TH-302 dose of 340 mg2 was identified for future studies. Skin and mucosal toxicity and myelosuppression were the most common TH-302 related AEs with no increase in treatment discontinuation. Disclosure All authors have declared no conflicts of interest.

Introduction. We had for objective to describe the updated epidemiology of oral cancers in France.Material and methods. Estimates made from data collected from various French cancer institutions. The distribution by topography, histology, regions, mean age, and specific incidence rates were calculated from the collected data. The survival data was taken from the Francim network studies.Results. Approximately 7000 oral cavity cancers were diagnosed in France in 2005. In 2007, 1746 people died of that cancer. Standardized (world population) incidence rates are respectively, in men and women, 12.3 and 3.0 cases per 100,000 person-years. These cancers have significantly decreased in men: the standardized incidence rate decreased by 43.2% between 1980 and 2005. Among women, the trend is reversed with an increased incidence of 51.7% over the same period.Conclusion. In France, the incidence of oral cavity cancers has been strongly decreasing in men and strongly increasing in women. This trend should be compared to the frequency of the main risk factors: alcohol and tobacco. (C) 2011 Elsevier Masson SAS. All rights reserved.

e20522 Background: The population-based cancer registry of the Lille Region (Northern France)-780,000 inhabitants covered-had been created in 2005, at the beginning of the French Plan against the Cancer and will allow the measure of the impact of undertaken actions. One of these actions was to promote the multidisciplinary decision making by dedicated regional or inter-regional committee(s). The present analysis is focused on adult sarcomas (AS) and the baseline situation in term of initial management at the beginning of the implementation of (inter-)regional sarcoma committees in 2005. A second work (2011) will analyze the management of the patient after the implementation of sarcoma committees. Methods: We have extracted from the registry all cases of AS recorded in 2005 to check the precise histological diagnosis and the initial treatment. All histological diagnosis have been reviewed. Only adult cases (≥18 years) had been retained. Results: Sixty-two cases were recorded in 2005 by the cancers registry. The crude and standardized (world standard poupulation) incidence rate for AS were respectively 10.3 per 100,000 person-year [95% CI: 7.8-12.9] and 9.9 per 100,000 person-year [95% CI: 7.3-12.4] (cases and person-pear≥ 18 years only).The median age was 57.5 (18-92). The sex ratio M/F was 0.48. The 4 most frequent primary sites were: soft tissue (23), bone (9), uterus (9) and retroperitoneum (6). The 4 most frequent histological types were: liposarcomas (13), mullerian mixte tumours (9), leiomyosarcomas (8) and angiosarcomas (6). There were 3 GIST, 2 Ewing sarcomas and 1 osteosarcoma. Nevertheless, at diagnosis, only 24 cases have been discussed in sarcoma committee (38.7%). This study suggests a higher incidence of sarcoma than expected according to literature data. About a third of cases have been discussed in appropriate committee at diagnosis. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer

The evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005 was analysed using data derived from the French network of cancer registries (FRANCIM) and the French National Mesothelioma Surveillance Program (PNSM). Mesothelioma proportions in pleural cancers were calculated by diagnosis year in the 1980-2000 period. Our results suggest that the incidences of pleural cancer and mesothelioma levelled off in French men since 2000 and continued to increase in French women. A decrease of the annual pleural cancer incidence average in men was noticed (-3.4% of annual rate of change) between 2000 and 2005. The proportion of pleural cancers that were mesothelioma was unchanged between 1980 and 2003 with an average of 86%. The age standardised incidence rate of pleural mesothelioma remained relatively stable between 1998 and 2005 with a slight falling trend. For women, the age standardised incidence rate of pleural cancers and mesothelioma increased during the period 1998-2005. Additionally, the proportion of pleural cancers that were mesothelioma increased during the same period of time. Finally, the increased trend observed in the incidence of pleural mesothelioma and cancers in women is credibly due to their under diagnosis in the 1980-1997 period. The comparison between the French incidence and the American and British ones shows that the decreasing trend in incidence of mesothelioma and pleural cancers in French men since 2000 is potentially associated with a lower amphibole consumption and by the implementation of safety regulations at work from 1977.